Pharmaceutical applications based on next generation sequencing technology in oncologic drug development
Turk Hijyen ve Deneysel Biyoloji Dergisi, ISSN: 0377-9777, Vol: 76, Issue: 4, Page: 473-486
2019
- 2Citations
- 12Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Review Description
In order to find an effective solution to the treatment of cancer disease, many international collaborative researches have been carried out and many promising results have been obtained from these on going studies. An effective solution has not yet been found for cancer disease but studies on the development of new treatment methods and the findings of the research results continue to be published. In this context, in the studies focusing on the treatment of cancer, the findings obtained after the use of advanced technologies have been used in personalized medicine and clinical applications. Nowadays, next-generation sequencing technologies, which provide information on genomes with genome sequencing, are one of the most advanced technologies used in cancer research. Next-generation sequencing technology examines both genes and identifies some mutations. This technique enables the identification of unknown sequence variations in a short time and more easily, thus enabling clinicians to better understand the mechanisms of cancer. In this review, we aimed to provide information about the availability of next generation sequencing technology in pharmaceutical applications including areas such as tumor marker determination to pharmacogenomics, targeted therapy, precision medicine, vaccine treatment, biopharmaceutics, polypharmocology, toxgonostics and pharmacoepidemiology.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85078908374&origin=inward; http://dx.doi.org/10.5505/turkhijyen.2019.33576; https://www.journalagent.com/z4/download_fulltext.asp?pdir=turkhijyen&plng=tur&un=THDBD-33576; https://dx.doi.org/10.5505/turkhijyen.2019.33576; https://jag.journalagent.com/turkhijyen/pdfs/THDBD_76_4_473_486.pdf
LookUs Bilisim A.S.
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know